Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 See also 2 References

Almitrine

●العربية ●Français ●Italiano ●Polski ●Português ●Српски / srpski ●Srpskohrvatski / српскохрватски Edit links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version In other projects ●Wikimedia Commons Appearance From Wikipedia, the free encyclopedia

This article needs additional citations for verification. Please help improve this articlebyadding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Almitrine" – news · newspapers · books · scholar · JSTOR (October 2011) (Learn how and when to remove this message)

Almitrine

Clinical data

AHFS/Drugs.com

International Drug Names

ATC code

R07AB07 (WHO)

Identifiers

IUPAC name

6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-N,N'-
diprop-2-enyl-1,3,5-triazine-2,4-diamine

CAS Number

27469-53-0^Y

PubChem CID

33887

DrugBank

DB01430^Y

ChemSpider

31235^Y

UNII

9A1222NBG4

KEGG

D07126^Y

ChEBI

CHEBI:53778^Y

ChEMBL

ChEMBL1183717^N

CompTox Dashboard (EPA)

DTXSID4057899

ECHA InfoCard

100.044.054

Chemical and physical data

Formula

C₂₆H₂₉F₂N₇

Molar mass

477.564 g·mol⁻¹

3D model (JSmol)

Interactive image

Melting point

181 °C (358 °F)

SMILES

Fc1ccc(cc1)C(c2ccc(F)cc2)N4CCN(c3nc(nc(n3)NC\C=C)NC\C=C)CC4

InChI

InChI=1S/C26H29F2N7/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20/h3-12,23H,1-2,13-18H2,(H2,29,30,31,32,33)^Y

Key:OBDOVFRMEYHSQB-UHFFFAOYSA-N^Y

^NY (what is this?) (verify)

Almitrine (marketed as DuxilbyServier) is a diphenylmethylpiperazine derivative classified as a respiratory stimulant by the ATC. It enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep. A significant literature exists for this compound, including over 60 papers that Medline labels as reviews.

The clinical efficacy of almitrine-raubasine combination therapy for age related cerebral disorders and functional rehabilitation after stroke has been reviewed by Allain and Bentué-Ferrer.^[1] They summarize two studies in which almitrine-raubasine improved some symptoms significantly more than placebo, especially in vascular cases. Their paper also suggests that other studies have shown a beneficial effect of this compound on neurosensory vascular disorders, specifically chorioretinal dysfunctions (visual symptomatology) and vertigo associated with electronystagmographic modifications. This paper further claims that the dosage and tolerance of the compound have been confirmed in a French multi-center study of 5,361 outpatients.

Under the brand names Albasine, Aruxil, and Truxil, almitrine-raubasine has been marketed for rehabilitation after stroke, age related neurological disorders, visual disorders related to circulation, and tinnitusinBangladesh.^[2]

References[edit]

^ Allain H, Bentué-Ferrer D (1998). "Clinical efficacy of almitrine-raubasine. An overview". European Neurology. 39 (Suppl. 1): 39–44. doi:10.1159/000052069. PMID 9516074. S2CID 46780859.